Instil Bio, Inc. (TIL) Profit Breakdown
- 2026-06-30: Reportable -$4.30M.
- 2025-06-30: Reportable -$21.39M.
Complete filed revenue-to-profit bridge showing gross profit, operating income, pre-tax income and net income.
- Available history
- 2020-03-31 to 2026-06-30
- Data captured
Profit by product
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | -$4.30M |
| 2025-06-30 | -$21.39M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |